Clinical trial
Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic…
NCT00221299 · University of California, Davis, Other · Completed
Key facts
| NCT number | NCT00221299 |
|---|---|
| Title | Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use |
| Official title | Can Risedronate and Parathyroid Hormone Reverse Glucocorticoid Induced Osteoporosis? |
| Lead sponsor | University of California, Davis, Other |
| Collaborators | University of California, San Francisco |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | Risedronate, Parathyroid Hormone |
| Enrollment | 60 |
| Start date | Sep 1, 2005 |
| Primary completion | Mar 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Sep 22, 2005 |
| Last update posted | Jun 25, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: